Skip to main content

Table 1 Baseline parameters, including body and liver weights, as well as post-treatment plasma metabolic markers of lean control (CkC), untreated db/db (DbC) and db/db mice treated with EMPA (DbE)

From: Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes

Parameter ANOVA CkC DbC DbE
P value (11) (12) (13)
Body weight
 Pre-treatment body weight (g) 0.001 18.9 ± 0.2 46.1* ± 0.7 45.4§ ± 0.7
 Post-treatment body weight (g) 0.001 19.2 ± 0.3 53.6* ± 1.0 53.5§ ± 0.7
 Delta (g) 0.001 0.17 ± 0.29 7.50* ± 0.76 8.32§ ± 0.50
 % Increase in body weight 0.001 0.7 ± 1.6 13.8* ± 1.3 15.5§ ± 0.9
Hepatic
 Liver weight (mg) 0.001 835 ± 37 2460*,† ± 92 2031§ ± 72
 Triglycerides (nmol g−1) 0.001 15 ± 3 43* ± 5 37§ ± 4
Plasma
 Cholesterol (mg dl−1) 0.001 76 ± 5 145* ± 3 148§ ± 6
 Triglycerides (mg dl−1) 0.001 126 ± 9 310* ± 18 301§ ± 20
 Alanine aminotransferase (U l−1) 0.001 27 ± 2 78* ± 5 69§ ± 8
  1. Values are mean ± SE. Post-hoc comparisons; P < 0.05 for * CkC vs DbC;  DbCvs DbE; and § CkC vs DbE. Sample sizes are noted in parentheses